Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Q32 Bio (QTTB) over the last 9 years, with Q3 2025 value amounting to $1.9 million.

  • Q32 Bio's Gains from Investment Securities fell 698.38% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 698.38%. This contributed to the annual value of $1.9 million for FY2024, which is 7467.98% up from last year.
  • Q32 Bio's Gains from Investment Securities amounted to $1.9 million in Q3 2025, which was down 698.38% from $1.9 million recorded in Q2 2025.
  • Over the past 5 years, Q32 Bio's Gains from Investment Securities peaked at $12.8 million during Q2 2023, and registered a low of -$49000.0 during Q4 2022.
  • In the last 5 years, Q32 Bio's Gains from Investment Securities had a median value of $2.2 million in 2024 and averaged $4.8 million.
  • Within the past 5 years, the most significant YoY rise in Q32 Bio's Gains from Investment Securities was 892095.65% (2024), while the steepest drop was 9809.35% (2024).
  • Quarter analysis of 5 years shows Q32 Bio's Gains from Investment Securities stood at $7.5 million in 2021, then plummeted by 100.65% to -$49000.0 in 2022, then skyrocketed by 8128.57% to $3.9 million in 2023, then tumbled by 98.09% to $75000.0 in 2024, then soared by 2384.73% to $1.9 million in 2025.
  • Its Gains from Investment Securities stands at $1.9 million for Q3 2025, versus $1.9 million for Q2 2025 and $328000.0 for Q1 2025.